Novo Nordisk has decided to replace its CEO, Lars Jørgensen, following a decline in stock performance. This move comes as the company faces intensifying competition, particularly from rival Eli Lilly in the weight-loss drug sector. Despite Novo Nordisk’s strong reputation, especially with its Wegovy drug, the decision reflects the challenges posed by market dynamics and the need to maintain an edge in pharmaceutical innovation.
— new from Barron’s